唾液酸化Tn抗原免疫放射分析竞争抑制法的基础与临床评估：（2）临床意义评估。STN研究组

[Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].

作者信息

Imura H, Mori T, Ohkura H, Ishii M, Ariyoshi H, Endo J, Kitao M, Takeda I, Kobayashi H, Inoue M

出版信息

Gan To Kagaku Ryoho. 1989 Sep;16(9):3221-30.

Abstract

The clinical significance of serum sialyl Tn antigen as a tumor marker was evaluated using "STN Otsuka" kits. Results indicated that the antigen was frequently elevated in sera from patients with ovarian cancers (43.1%, 140/325), including serous cystadenocarcinoma (51.6%, 63/122), mucinous cystadenocarcinoma (55.6%, 30/54), endometrioid carcinoma (56.5%, 13/23), and mesonephroid carcinoma (40.0%, 6/15). The positive frequency of sialyl Tn antigen in patients with ovarian carcinoma was less than the frequency of CA 125 (75.5%, 194/257) or sialyl SSEA-1 (47.2% 83/176). However, the false positive rate of sialyl Tn antigen in patients with benign gynecological disorders (3.7%, 15/401) was much lower than the false positive rates of other antigens; such as CA 125 (48.4%, 155/320) and sialyl SSEA-1 (19.2%, 51/266). The serum level of sialyl Tn antigen reflected the clinical activity of the disease quite well in patients with ovarian cancers. The sialyl Tn antigen was concluded to be a useful serum tumor marker for ovarian cancers.

摘要

使用“STN大冢”试剂盒评估血清唾液酸Tn抗原作为肿瘤标志物的临床意义。结果表明，该抗原在卵巢癌患者血清中经常升高（43.1%，140/325），包括浆液性囊腺癌（51.6%，63/122）、黏液性囊腺癌（55.6%，30/54）、子宫内膜样癌（56.5%，13/23）和中肾样癌（40.0%，6/15）。卵巢癌患者中唾液酸Tn抗原的阳性频率低于CA 125（75.5%，194/257）或唾液酸SSEA-1（47.2%，83/176）。然而，良性妇科疾病患者中唾液酸Tn抗原的假阳性率（3.7%，15/401）远低于其他抗原，如CA 125（48.4%，155/320）和唾液酸SSEA-1（19.2%，51/266）。唾液酸Tn抗原的血清水平在卵巢癌患者中很好地反映了疾病的临床活动情况。得出结论，唾液酸Tn抗原是一种用于卵巢癌的有用血清肿瘤标志物。